<doc>
  <docmeta id="113s1322is">
    <bill congress="113" type="s" number="1322" version="is"/>
    <revision size="2675" annotations="0" status="complete" id="5" commit-time="2013-08-07T21:52:25Z" committer="mbohmer" doc="113s1322is/5.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata>
<dublinCore>
<title>113 S1322 IS: SALTS Act</title>
<publisher>U.S. Senate</publisher>
<date>2013-07-18</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 1322</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130718">July 18, 2013</action-date>
			<action-desc>
        <sponsor name-id="S311">Ms. Klobuchar</sponsor> (for
			 herself, <cosponsor name-id="S293">Mr. Graham</cosponsor>, and
			 <cosponsor name-id="S221">Mrs. Feinstein</cosponsor>) introduced the following
			 bill; which was read twice and referred to the
			 <committee-name committee-id="SSJU00">Committee on the
			 Judiciary</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Controlled Substances Act relating to
		  controlled substance analogues. </official-title>
	</form>
	<legis-body>
		<section id="id181A23D686AF469DBE0E5BEEA0422D6E" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Synthetic Abuse and Labeling of Toxic
			 Substances Act of 2013</short-title>
        </quote> or the <quote>SALTS
			 Act</quote>.</text>
		</section>
    <section id="id10D114B5ACA94FE1B7145CB2EE1B864C" section-type="subsequent-section">
      <enum>2.</enum>
      <header>Controlled substance
			 analogues</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:203">Section 203 of the
			 Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/813">
            <cato:entity-ref entity-type="uscode" value="usc/21/813">21 U.S.C. 813</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text>
			<paragraph id="id2A6C6D2757144DD3B6FA4159E53942CA">
        <enum>(1)</enum>
        <text>by striking
			 <quote>A controlled</quote> and inserting <quote>(a)
			 <header-in-text level="subsection" style="OLC">In general</header-in-text>.—A
			 controlled</quote>; and</text>
			</paragraph>
      <paragraph id="id03199480C98F43B5A6429DC8A3B1FBBB">
        <enum>(2)</enum>
        <text>by adding at the
			 end the following:</text>
				<quoted-block display-inline="no-display-inline" id="id80EE26A65B8B4244AE732977A2E3795C" style="OLC">
					<subsection id="idA13896C2F54E438F9E8F16A47E87D02F">
            <enum>(b)</enum>
            <header>Determination</header>
            <text>In
				determining whether a controlled substance analogue was intended for human
				consumption under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:203/ss:a">subsection (a)</cato:entity-ref>, the following factors may be considered,
				along with any other relevant factors:</text>
						<paragraph id="id74813ba469d84b8eacb1f15381b7de05">
              <enum>(1)</enum>
              <text>The marketing,
				advertising, and labeling of the substance.</text>
						</paragraph>
            <paragraph id="ide3d777d52ab64a8c9dfa428703a44c4c">
              <enum>(2)</enum>
              <text>The known
				efficacy or usefulness of the substance for the marketed, advertised or labeled
				purpose.</text>
						</paragraph>
            <paragraph id="id37ff210446df4ab78868aa35776109e0">
              <enum>(3)</enum>
              <text>The difference
				between the price at which the substance is sold and the price at which the
				substance it is purported to be or advertised as is normally sold.</text>
						</paragraph>
            <paragraph id="id6da3061a85ad4bb4bcd4054a26665e1f">
              <enum>(4)</enum>
              <text>The diversion of
				the substance from legitimate channels and the clandestine importation,
				manufacture, or distribution of the substance.</text>
						</paragraph>
            <paragraph id="id7d2e30f28d734fe29389380fa4ec4c10">
              <enum>(5)</enum>
              <text>Whether the
				defendant knew or should have known the substance was intended to be consumed
				by injection, inhalation, ingestion, or any other immediate means.</text>
						</paragraph>
          </subsection>
          <subsection commented="no" display-inline="no-display-inline" id="ida59a47467e5d416bb89f39995dc2bb2c">
            <enum>(c)</enum>
            <header>Limitation</header>
            <text>For
				purposes of this section, evidence that a substance was not marketed,
				advertised, or labeled for human consumption, by itself, shall not be
				sufficient to establish that the substance was not intended for human
				consumption.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</paragraph>
    </section>
  </legis-body>
</bill>
</doc>